Wednesday, July 8, 2026

Patent intelligence · US

US 10987360

Hepatitis B core protein modulators

granted A61KA61K31/426A61K31/427A61K31/454
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 14
Patent details — US 10987360
Jurisdiction
US
Status
granted
Grant date
Apr 27, 2021
Expiration
Apr 22, 2041
Claims
16
CPC classes
A61K, A61K31/426, A61K31/427, A61K31/454
View on Google Patents ↗

Quick answer

US 10987360 (Hepatitis B core protein modulators) is held by ASSEMBLY BIOSCIENCES, INC.. Status: granted. Granted Apr 27, 2021. Expires Apr 22, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K31/426, A61K31/427, A61K31/454, A61K31/554, A61P

More from ASSEMBLY BIOSCIENCES, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12030869

    5-membered heteroaryl carboxamide compounds for treatment of HBV

    ASSEMBLY BIOSCIENCES, INC. · Expires Jul 4, 2044

    granted
  2. US 11814376

    Hepatitis b core protein modulators

    ASSEMBLY BIOSCIENCES, INC. · Expires Nov 9, 2043

    granted
  3. US 11560370

    5-membered heteroaryl carboxamide compounds for treatment of HBV

    ASSEMBLY BIOSCIENCES, INC. · Expires Jan 19, 2043

    granted
  4. US 11331365

    Multispecific protein drug and library thereof, preparing method therefor and application thereof

    Assembly Medicine, LLC · Expires May 12, 2042

    granted
  5. US 11078170

    Cyclic sulfamide compounds and methods of using same

    ASSEMBLY BIOSCIENCES, INC. · Expires Jul 29, 2041

    granted
  6. US 11040965

    Process for making Hepatitis B core protein modulators

    ASSEMBLY BIOSCIENCES, INC. · Expires Jun 17, 2041

    granted
  7. US 10968211

    Hepatitis B core protein modulators

    ASSEMBLY BIOSCIENCES, INC. · Expires Apr 1, 2041

    granted

Frequently asked questions

What is US patent 10987360?

US 10987360 (Hepatitis B core protein modulators) is held by ASSEMBLY BIOSCIENCES, INC.. Status: granted. Granted Apr 27, 2021. Expires Apr 22, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10987360?

ASSEMBLY BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.

When does US 10987360 expire?

Our index shows an expiration date of Apr 22, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.